This study is looking at whether a combination of two drugs, atezolizumab and tiragolumab, can help people with high-risk urothelial carcinoma (a type of bladder cancer) that cannot be treated with cisplatin chemotherapy. These drugs are given by vein (IV) before surgery to remove the bladder and tumor. The study aims to see how long patients live without their cancer returning (relapse-free survival) and how long they live overall (overall survival), both measured for about one year after the study starts. You may be able to join if you are over 18, have muscle-invasive urothelial cancer, and meet other specific health requirements. The study is currently unclear about its recruitment status and plans to enroll 10 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 10 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for relapse-free survival and overall survival through study completion, an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.